4 hours ago
1
Grandbrothers/iStock Editorial via Getty Images
Greenwich LifeSciences (NASDAQ:GLSI) added ~32% in the premarket on Wednesday after the U.S. FDA issued its Fast Track designation for its lead asset GLSI-100 to treat a subset of breast cancer patients.
Specifically, the FDA has granted Fast Track status for
© FBT Company 2025. All rights are reserved
English (US) ·